Findings

What do systematic reviews say?

2 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 8 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo

Interferon + SSA (2 RCTs; 171 participants)

It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon + SSA (2 RCTs; 468 participants) compared with placebo (very low certainty).

4 findings from 1 review

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
HR 0.34 [0.14, 0.8]
2 studies · 468 participants
Very low
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 5.71 [1.9, 17.2]
4 studies · 283 participants
Very low
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
HR 0.23 [0.06, 0.93]
3 studies · 512 participants
Very low

Show 1 more finding

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 2.88 [1.16, 7.13]
2 studies · 171 participants
Very low

Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo

Interferon (1 RCT; 66 participants)

It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon (1 RCT; 66 participants) compared with placebo (very low certainty).

4 findings from 1 review

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
HR 0.41 [0.18, 0.94]
1 study · 66 participants
Very low
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 4.03 [0.86, 18.8]
2 studies · 86 participants
Very low
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
HR 0.27 [0.07, 1.1]
1 study · 66 participants
Very low

Show 1 more finding

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 2.58 [0.75, 8.81]
1 study · 66 participants
Very low